Petition pushes FDA to exempt AI devices from premarket review

Sure, here are four key points summarized from the article:

– Mario Aguilar writes about various aspects of technology in healthcare, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics, focusing on the changes, business, and policy challenges these technologies bring to healthcare.

– Katie Palmer also covers topics related to telehealth and clinical artificial intelligence, particularly the impacts of digital healthcare on patients, providers, and businesses.

– AI company Harrison.ai has proposed to the FDA that certain AI products used by radiologists to analyze medical images could be released into the market without review. This would require the FDA to have previously cleared a relevant product from the same manufacturer and for developers to follow specific technical standards and monitoring plans.

– The FDA is considering this proposal and has appointed a former senior executive from a subsidiary of Harrison.ai to direct the office that informs policy on AI. If the FDA does not deny the petition by mid-April, the proposal will go into effect automatically.